NCT06388720View on ClinicalTrials.gov

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Bladder Cancer
Interventions
DRUG

Mitomycin-C

Intravesical instillation of Mitomycin-c 40 mg in 20 ml as the first agent in sequential treatment.

DRUG

gemcitabine

Intravesical instillation of Gemcitabine 2000 mg in 50 ml following Mitomycin-c administration.

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center, Goyang-si

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV